europe
koya979 / shutterstock.com
23 August 2016Big Pharma

Gilead’s Truvada approved by European Commission

Gilead Sciences has received marketing authorisation from the European Commission for its drug Truvada (tenofovir disoproxil/emtricitabine).

Truvada is used to reduce the risk of acquiring HIV-1 infection, and is aimed at adults who are at high-risk of infection.

The drug enables a strategy known as pre-exposure prophylaxis, or PrEP.

The authorisation, which was announced yesterday, August 22, allows for the marketing of Truvada in all 28 countries of the EU.

Norbert Bischofberger, vice president at Gilead, said: “The approval of Truvada for PrEP represents an important step forward in addressing the incidence of HIV in Europe.”

He added: “When taken as directed and used in combination with other prevention strategies, Gilead believes Truvada for PrEP can have a meaningful impact on public health by helping to reduce HIV transmission rates across Europe.”

Truvada is also authorised for PrEP in Australia, Canada, Kenya, Peru, South Africa and the US.

Earlier this month,  LSIPR reported that the English High Court ruled that the National Health Service (NHS) England should finance the PrEP therapy.

The NHS previously claimed that it does not have the legal power to commission drugs that enable PrEP because it is up to local authorities to finance HIV services.


More on this story

Americas
9 May 2019   A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.

More on this story

Americas
9 May 2019   A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.